Page 67 - ADD-ON ABLATION SURGERY IN PATIENTS WITH ATRIAL FIBRILLATION

Chapter 8
184
Table 2. Surgery First Author
Source Method
Access
Roof Inf A-LA IL RA LAA
GP CTL CSL
Mahapatra S.17 Krul S.P.J18 La Meir M.19 Pison L.20
La Meir M. 21 Zembala M.22 Muneretto C.23 Gehi A.K24.
RF (b)I VATS RF(b) I VATS RF (b)I VATS RF(b) I VATS RF(u) I VATS RF(u) I VALS
B-Thor B-Thor B-Thor B-Thor R-Thor
Y - Y - Y 14/15
Y YY Y ns - Y 3/35 - Y 2/26 - Y 2/19 -
RF(u) VATS RF(u) I VATS Bisleri G.25 RF(u) VATS
-Y3/19- - LAP Y Y - - - R-Thor YY-- - SubX 90/101 97/101 Y 84/101 - R-Thor Y Y - - -
Y - Y - - Y ns -
Table 3. End-points and rhythm monitoring
First Author
F-Up (m)
Completeness
F-Up type End-point
Rhythm Monitoring
AAD
OA
Mahapatra S.17 Krul S.P.J18 La Meir M.19 Pison L.20
La Meir M. 21 Zembala M.22*** Muneretto C.23 Gehi A.K24. Bisleri G.25
20.4±4.5 24 24
*
24 24 30 12 28.4±1.7
15/15 (100%) 22/31 (70.9%) 35/35 (100%) 24/26 (92.3%) 19/19 (100%) 18/27 (66.6%) 36/36 (100%) 101/101 (100%) 45/45 (100%)
OC 1
EKG; 7d CAT; 24h HM EKG; 24h HM EKG; 7d HM EKG; 7d HM EKG; 7d HM
24h HM
6.6% ns 26%** ns 26%** ns
ns 48.3% 29%** ns 48.2%** ns
ns
ns
ns
13/31 31/35 23/26
8/31 32/35 22/26
13/31 - -
Y 7/35 23/35 Y 3/26 8/26
29/31 15/35 Y
-
Studies were presented by year of publication. Abbreviations: Source: RF: Radiofrequency; b: bipolar; u: unipolar; I. Irrigated; Method:VATS: video assisted thoracoscopic surgery;VALS:Video assisted Laparoscopy ;Access: R-Thor: Right Thorachoscopy; B-Thor:Bilateral Thorachoscopy; LAP: Laparoscopy; SubX: Subxiphoid; Roof: Roof line; Inf: Inferior line;A-LA:Additional Left Atrial lines; IL: Isthmus line.Y: RA: Right atrial and caval lines, LAA: Left atrial appendage excision/closure; GP: Ganglionated plexi ablation; CTL Cavo-tricuspid line; CSL: Coronary sinus line;Y:Yes; ns: not specified
OC 2 OC;CV 3 OC ;CV 3 OC;CV 4 OC 5 OC 6 OC 7 OC 6
ICM 22.2% 24h HM 37%
Studies were presented by year of publication. Abbreviations: F-Up: Follow-up; m=months; AAD: (%patients taking) Antiarrhythmic Drugs; OA:
Anticoagulants. Endpoint: 1: Event-free survival of any atrial arrhythmia longer than 30 seconds off AAD; 2: Freedom from episodes of AF, atrial flutter or tachycardia, without the use of AAD after 12 months;3: No AT, AF or Atrial Flutter lasting >30 seconds off antiarrhythmic drugs;4.AF prevalence; 5: Patients in AF; 6 Absence of AF
ICM ns
- - 99/101
73/101 - - ns -
(%patients taking) Oral